By Hassan Zaggi
The Director General of the National Institute for Pharmaceutical Research and Development (NIPRD), Dr. Obi Adigwe, has disclosed that his Institute has concluded plans to turn around the economy of the Nigeria.
He stated this while presenting the score card of his stewardship since his appointment by President Muhammadu Buhari 12 months ago.
It would be recalled that in the last week of August 2018, President Muhammadu Buhari approved the appointment of Dr. Adigwe as the director general of NIPRD.
According to him, in the past one year, “I have consistently advocated for innovative concepts that aimed at improving sustainable access to safe, high quality and affordable healthcare, through local production of medicines and commodities, as well as making significant impact on relevant socioeconomic variables, which include job creation, knowledge transfer and revenue generation.
“Currently the Institute’s position as the Continent’s prime destination for Pharma and related Research and Development is evidenced by the attainment of ISO 9001 : 2008, ISO/IEC 17025 : 2017 as well as the ANDI Centre for Excellence in the African Sub-Region.”
He noted that despite the fact that he inherited many challenges ranging from infrastructural decay to poor staff welfare, he continued to initiate developmental and innovative ideas with a view to repositioning the Institute and bringing her to limelight steadily.
Adigwe listed some of his achievements since the past 12 months to include: “Successful hosting of the Pharmaceutical Industry Discourse focused on the relationships between Health Education and engagement tagged (NIPRD-HEEAD), where eminent personalities from the Pharma Industry interacted with Legislators and policy makers to deliberate on strategies for developing a robust and comprehensive policy to catalyse pharma industrial development.
“Engagement with over 40 Directors General and Chief Executive Officers of various MDAs and Organisations, including 7 Vice Chancellors for collaborative working towards improving the business environment and attaining Executive Order No. 1.
“This approach has led to significant gains for the Institute, including training of staff abroad, receipt of laptops by close to 90% of staff, prospective memoranda of understanding (MOUs) signed, and overall improved morale among staff.
“Developing an intensive backward integration plan to stimulate local product of excipients, pharma inputs and other relevant raw materials.
“Recontextualising existing research to address National and Regional healthcare and socioeconomic needs. “Increasing collaborative engagement with Nigerian and foreign universities. This ensures that such partnerships are leveraged, to gain access to cutting edge interventions, while ensuring that they are suitably contextualised for our setting.
“Initiating strategic partnerships with other similar Institutes and Agencies with synergistic objectives. The Institute recently hosted potential partners from Germany and Italy for Bioavailability/Bioequivalence and Aflatoxin Research respectively.”